Clinical Trial Update: Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SAR153191 (REGN88) with methotrexate in active rheumatoid arthritis patients who failed TNF-α blockers; the study was terminated with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• SAR153191 (REGN88) (SAR153191)

Snippet

Sponsor: Sanofi | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2017-09-01